Guardant blood test shows promise in predicting immunotherapy response; AstraZeneca's diabetes drug wins EU label expansion
→ The field of liquid biopsy is burgeoning, and each player (there are plenty) is doggedly pursuing consistency and accuracy — false positives induce unnecessary anxiety, and are costly. Late on Sunday, Guardant Health said its assay, Guardant360, showed in a study it can accurately detect microsatellite instability (MSI), a key biomarker used to predict response to immunotherapy regardless of tumor type. MSI is a change that occurs in the DNA of certain cells (such as tumor cells) in which the number of repeats of microsatellites (short, repeated sequences of DNA) is different than the number of repeats that was in the DNA when it was inherited.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.